10-Q: GlobeStar Therapeutics Reports Q3 2024 Results, Shifts Business Focus Away From Multiple Sclerosis Treatments

GlobeStar Therapeutics reports a net loss for Q3 2024 and announces a shift in business focus away from Multiple Sclerosis treatments.

Summary

• GlobeStar Therapeutics Corporation reported its financial results for the third quarter of 2024.
• The company had no revenue for the three and nine months ended June 30, 2024 and 2023.
• The net loss for the three months ended June 30, 2024, was $197,661, compared to a net loss of $1,282,529 for the same period in 2023.
• The net loss for the nine months ended June 30, 2024, was $536,382, compared to a net loss of $1,598,675 for the same period in 2023.
• As of June 30, 2024, the company had cash and cash equivalents of $41 and a negative working capital of $1,624,932.
• The company's management has expressed substantial doubt about its ability to continue as a going concern without additional capital.
• GlobeStar Therapeutics is shifting its business focus away from Multiple Sclerosis treatments and intends to terminate its license agreement with 7 to Stand.
• The company was notified of an action against it related to incomplete Regulation D filings and was assessed $30,000 in fines.
• The company intends to vigorously defend against this action.
• Steven Penderghast resigned as a member of the Board of Directors on September 28, 2024.
• The company acknowledges material weaknesses in its internal controls over the control environment and financial statement disclosure.

Sentiment

Score: 2

Explanation: The document paints a bleak picture of the company's financial health and future prospects, with a very weak cash position, negative working capital, and abandonment of its core business strategy. The acknowledgement of material weaknesses in internal controls and the potential for a $30,000 fine further contribute to the negative sentiment.

Positives

• The net loss decreased significantly in Q3 2024 compared to Q3 2023, from $1,282,529 to $197,661.
• General and administrative expenses decreased due to a decrease in stock compensation to officers and consultants.
• Interest expense decreased due to the conversion of convertible notes payable and accrued interest.

Negatives

• The company has a very weak cash position, with only $41 in cash and cash equivalents as of June 30, 2024.
• The company has a negative working capital of $1,624,932 as of June 30, 2024.
• Management expresses substantial doubt about the company's ability to continue as a going concern without additional capital.
• The company is abandoning its Multiple Sclerosis treatment program, which was a key part of its business plan.
• The company faces a $30,000 fine related to incomplete Regulation D filings.
• The company acknowledges material weaknesses in its internal controls over the control environment and financial statement disclosure.
• The company had no revenue for the three and nine months ended June 30, 2024 and 2023.

Risks

• The company's ability to continue as a going concern is highly uncertain due to its weak financial position and lack of revenue.
• The company's abandonment of its Multiple Sclerosis treatment program could negatively impact its future prospects.
• The $30,000 fine related to incomplete Regulation D filings could indicate compliance issues.
• The material weaknesses in internal controls could lead to errors or fraud in financial reporting.
• The company's reliance on additional financing to continue operations is a significant risk, as there is no guarantee that such financing will be available.

Future Outlook

The company's future is highly uncertain, contingent on securing additional financing and achieving profitability, with a shift in business strategy away from Multiple Sclerosis treatments.

Management Comments

• Management does not anticipate having positive cash flow from operations in the near future.
• Without additional capital, the Company will not be able to remain in business.
• Management plans to continue to focus on raising the funds necessary to implement the Company's business plan.
• Management will continue to seek out debt financing to obtain the capital required to meet the Company's financial obligations.

Industry Context

The company's shift away from pharmaceutical development and its financial struggles highlight the challenges faced by small biotech companies in a competitive and capital-intensive industry.

Comparison to Industry Standards

• Given the lack of revenue and extremely low cash balance, GlobeStar Therapeutics' financial position is significantly weaker than many comparable companies in the pharmaceutical or biotechnology sectors.
• Many early-stage biotech companies rely on venture capital or strategic partnerships to fund their research and development activities, which GlobeStar appears to be struggling to secure.
• The company's decision to abandon its Multiple Sclerosis treatment program is a major setback, as MS is a large and growing market with significant unmet needs.
• Compared to larger pharmaceutical companies with diversified product portfolios, GlobeStar's reliance on a single licensed technology made it particularly vulnerable to strategic shifts.

Management Changes

Legal Proceedings

• The Company was notified of an action against the Company related to incomplete Regulation D filings by the State of Washington Department of Financial Institutions Securities Division and was assessed $30,000 in fines.
• The Company intends to vigorously defends against this action.

Related Party Transactions

• As of June 30, 2024 and September 30, 2023, the Company owed $ 659,771 and $ 454,665 to officers of the Company for compensation which are recorded as accounts payable related party.
• During the six months ended March 31, 2024 and 2023, the Companys CEO paid expenses of $ 9,000 and $ 0 and was repaid $ 9,000 and $ 0 , respectively.
• Additionally, during the six months ended March 31, 2024 and 2023, the Company received short term, unsecured, non-interest bearing advances from the Companys CEO and CFO totaling $ 1,684 and $ 700 , respectively.
• As of March 31, 2024 and September 30, 2023, the Company owed $ 7,979 and $ 6,295 on these related party advances, respectively.

Stakeholder Impact

• Shareholders face significant risk due to the company's weak financial position and uncertain future.
• Employees may be impacted by the company's shift in business strategy and potential need for cost-cutting measures.
• Creditors face increased risk of non-payment due to the company's financial difficulties.
• The termination of the license agreement with 7 to Stand will impact that company's future prospects.

Next Steps

• The company intends to vigorously defend against the action related to incomplete Regulation D filings.
• The Company intends to terminate its license agreement with 7 to Stand.
• The company will need to secure additional financing to continue operations.
• The company will need to develop a new business plan following the decision to no longer pursue its potential treatments for Multiple Sclerosis and other neurodegenerative diseases.

Key Dates

Keywords

financial results, net loss, going concern, multiple sclerosis, pharmaceutical, convertible notes, stock compensation, internal controls, regulation D, GlobeStar Therapeutics